Biohaven Q2 net loss narrows on lower R&D spend
BHVN•Outlook
- Company expects topline results from Phase 2/3 RISE3 epilepsy trial in 2H 2026
- Biohaven plans to initiate pivotal Phase 3 study for BHV-1400 in IgAN in 2H 2026
- Company expects topline data from Phase 2 obesity study with taldefgrobep alfa in 2H 2026
Analyst coverage
- The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 3 "hold" and 1 "sell" or "strong sell"
- The average consensus recommendation for the biotechnology & medical research peer group is "buy"
- Wall Street's median 12-month price target for Biohaven Ltd. is $20.50, about 39.8% above its August 7 closing price of $14.66
Quarterly results and cost drivers
- U.S. biopharma firm's Q2 net loss narrowed yr/yr on lower R&D and preclinical spending
- Q2 operating expenses fell sharply after strategic reprioritization of programs
- Company advanced pivotal trials in Graves disease and IgA nephropathy, with multiple pipeline updates
Result drivers
- R&D expense reduction - Co attributed lower Q2 R&D expenses to strategic reprioritization of programs and absence of prior-year milestone payments
